Association of Haemoglobin Glycation Index with All-cause and Cardiovascular Disease Mortality in Diabetic Kidney Disease: a Cohort Study

Overview

Journal Diabetol Metab Syndr

Publisher Biomed Central

Specialty Endocrinology

Date 2024 Sep 11

PMID 39261957

Authors

Lihua Huang

Liuliu He

Xiaoyan Luo

Xiaoqing Zhou

Affiliations

Soon will be listed here.

Abstract

Background: While the high haemoglobin glycation index (HGI) has been extensively investigated in diabetic populations, its impact on patients with diabetic kidney disease (DKD) remains unclear.

Methods: We examined data from the National Health and Nutrition Examination Surveys (NHANES) conducted between 1999 and 2018. HGI was determined using the formula recommended by Hempe et al., which calculates the difference between measured and predicted HbA1c. Predicted HbA1c was derived from the equation: 0.024 FPG + 3.1. National death index records up to December 31, 2019, were utilized to assess mortality outcomes. To estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for both all-cause and cardiovascular disease (CVD) mortality, we utilized Cox proportional hazard models. A restricted cubic spline analysis was performed to explore the potential nonlinear relationship between HGI levels and mortality.

Results: Our cohort study comprised data from 1,057 participants with DKD (mean [SE] age, 61.61 [0.57] years; 48.24% female). The mean HGI level was 0.44 (SE 0.04). Over a median follow-up period of 6.67 years, we observed 381 deaths, including 140 due to CVD. Compared with participants in the second tertile of HGI levels (0.03-0.74), those in the lowest tertile of HGI (-5.29-0.02) exhibited an all-cause mortality hazard ratio of 1.39 (95% CI, 1.02-1.88) and a CVD mortality hazard ratio of 1.10 (95% CI, 0.67-1.81). Conversely, participants in the highest tertile (0.75-9.60) demonstrated an all-cause mortality hazard ratio of 1.48 (95% CI, 1.05-2.08) and a CVD mortality hazard ratio of 2.06 (95% CI, 1.13-3.77) after further adjusting for HbA1c and other important variables. Additionally, a restricted cubic spline analysis revealed a U-shaped relationship between HGI and all-cause mortality (P < 0.001 for nonlinearity) and a J-shaped relationship between HGI and CVD mortality (P = 0.044 for nonlinearity).

Conclusions: Our cohort study suggests that HGI in DKD populations exhibits a U-shaped association with all-cause mortality and a J-shaped association with CVD mortality, independent of HbA1c levels.

References

de Boer I, Rue T, Hall Y, Heagerty P, Weiss N, Himmelfarb J . Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011; 305(24):2532-9. PMC: 3731378. DOI: 10.1001/jama.2011.861. View

Wu J, Liang D, Xie Y, Chen M, Chen H, Sun D . Association Between Hemoglobin Glycation Index and Risk of Cardiovascular Disease and All Cause Mortality in Type 2 Diabetic Patients: A Meta-Analysis. Front Cardiovasc Med. 2021; 8:690689. PMC: 8193090. DOI: 10.3389/fcvm.2021.690689. View

Zhang L, Wang M, Zhang R, Zhong Y, Fan H, Wang M . Hemoglobin glycation index in relationship to the risk of cardiovascular complication in patients with type 2 diabetes: A systematic review and meta-analysis. J Diabetes Complications. 2020; 34(10):107673. DOI: 10.1016/j.jdiacomp.2020.107673. View

Shah M, Brownlee M . Molecular and Cellular Mechanisms of Cardiovascular Disorders in Diabetes. Circ Res. 2016; 118(11):1808-29. PMC: 4888901. DOI: 10.1161/CIRCRESAHA.116.306923. View

Stauffer M, Fan T . Prevalence of anemia in chronic kidney disease in the United States. PLoS One. 2014; 9(1):e84943. PMC: 3879360. DOI: 10.1371/journal.pone.0084943. View

Snieder H, Sawtell P, Ross L, Walker J, Spector T, Leslie R . HbA(1c) levels are genetically determined even in type 1 diabetes: evidence from healthy and diabetic twins. Diabetes. 2001; 50(12):2858-63. DOI: 10.2337/diabetes.50.12.2858. View

Hempe J, Yang S, Liu S, Hsia D . Standardizing the haemoglobin glycation index. Endocrinol Diabetes Metab. 2021; 4(4):e00299. PMC: 8502217. DOI: 10.1002/edm2.299. View

Marini M, Fiorentino T, Succurro E, Pedace E, Andreozzi F, Sciacqua A . Association between hemoglobin glycation index with insulin resistance and carotid atherosclerosis in non-diabetic individuals. PLoS One. 2017; 12(4):e0175547. PMC: 5398507. DOI: 10.1371/journal.pone.0175547. View

Lin C, Lai Y, Chang T, Jiang Y, Chang Y, Chuang L . Hemoglobin glycation index predicts renal function deterioration in patients with type 2 diabetes and a low risk of chronic kidney disease. Diabetes Res Clin Pract. 2022; 186:109834. DOI: 10.1016/j.diabres.2022.109834. View

10.

Nathan D, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine R . Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008; 31(8):1473-8. PMC: 2742903. DOI: 10.2337/dc08-0545. View

11.

Hempe J, Liu S, Myers L, McCarter R, Buse J, Fonseca V . The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial. Diabetes Care. 2015; 38(6):1067-74. PMC: 4439529. DOI: 10.2337/dc14-1844. View

12.

. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

13.

Kim M, Jeong J, Yun J, Kwon H, Baek K, Song K . Hemoglobin glycation index predicts cardiovascular disease in people with type 2 diabetes mellitus: A 10-year longitudinal cohort study. J Diabetes Complications. 2018; 32(10):906-910. DOI: 10.1016/j.jdiacomp.2018.08.007. View

14.

Cosson E, Banu I, Cussac-Pillegand C, Chen Q, Chiheb S, Jaber Y . Glycation gap is associated with macroproteinuria but not with other complications in patients with type 2 diabetes. Diabetes Care. 2013; 36(7):2070-6. PMC: 3687281. DOI: 10.2337/dc12-1780. View

15.

McCarter R, Hempe J, Gomez R, Chalew S . Biological variation in HbA1c predicts risk of retinopathy and nephropathy in type 1 diabetes. Diabetes Care. 2004; 27(6):1259-64. DOI: 10.2337/diacare.27.6.1259. View

16.

Gonzalez-Covarrubias V, Sanchez-Ibarra H, Lozano-Gonzalez K, Villicana S, Texis T, Rodriguez-Dorantes M . Transporters, TBC1D4, and ARID5B Variants to Explain Glycated Hemoglobin Variability in Patients with Type 2 Diabetes. Pharmacology. 2021; 106(11-12):588-596. DOI: 10.1159/000517462. View

17.

Hempe J, Gomez R, McCarter Jr R, Chalew S . High and low hemoglobin glycation phenotypes in type 1 diabetes: a challenge for interpretation of glycemic control. J Diabetes Complications. 2002; 16(5):313-20. DOI: 10.1016/s1056-8727(01)00227-6. View

18.

Chalew S, McCarter R, Thomas J, Thomson J, Hempe J . A comparison of the Glycosylation Gap and Hemoglobin Glycation Index in patients with diabetes. J Diabetes Complications. 2005; 19(4):218-22. DOI: 10.1016/j.jdiacomp.2005.01.004. View

19.

Krebs-Smith S, Pannucci T, Subar A, Kirkpatrick S, Lerman J, Tooze J . Update of the Healthy Eating Index: HEI-2015. J Acad Nutr Diet. 2018; 118(9):1591-1602. PMC: 6719291. DOI: 10.1016/j.jand.2018.05.021. View

20.

Zhang X, Wei R, Wang X, Zhang W, Li M, Ni T . The neutrophil-to-lymphocyte ratio is associated with all-cause and cardiovascular mortality among individuals with hypertension. Cardiovasc Diabetol. 2024; 23(1):117. PMC: 10985955. DOI: 10.1186/s12933-024-02191-5. View